SLC2A4 and Cognitive impairment: 200 mg/kg: Significant reduction in body weight, blood lipids (TC, TG, LDL-C), fasting blood glucose (FBG); improvement in HOMA-IR, insulin levels, and sensitivity; reduction in liver fat accumulation; regulation of lipid metabolism genes (Glut4 ↑, Fasn ↓, Cebpa ↓); improvement in anxiety (elevated plus maze) and cognitive impairments (water maze); increased hippocampal BDNF and GABA_A expression; decreased inflammation markers (TNF-α, IL-1β).